RxDoctor Payments Data

William Bohlke, MD

Family Medicine · Brooklet, GANPI 1225141997

Payments from drug & device makers

$8,124in general payments, 2019–2025

Across 483 payments — averaging $16.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • AbbVie$847
  • Lilly USA, LLC$693
  • Amgen$529
  • Pfizer$528
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$8,094100%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,124 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$234,986
Medicare patients
463
Services billed
4,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx SyringeSecukinumab11$94,701
EliquisApixaban104$91,392
FarxigaDapagliflozin Propanediol63$66,903
EntrestoSacubitril/Valsartan53$60,374
OzempicSemaglutide43$54,856
RybelsusSemaglutide34$44,758
JanuviaSitagliptin Phosphate28$32,023
ArexvyRsvpref3 Antigen/As01e/Pf99$31,754
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$28,494
XareltoRivaroxaban35$27,110
MounjaroTirzepatide19$26,820
LinzessLinaclotide25$25,811
JardianceEmpagliflozin23$22,082
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$14,155
JanumetSitagliptin Phos/Metformin Hcl17$13,778

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,103$99,61477 claims
PfizerEliquis$528$91,392104 claims
GSKArexvy, Trelegy Ellipta, Shingrix, Breo Ellipta$136$77,407197 claims
AstraZenecaFarxiga, Symbicort$1,390$71,04177 claims
NovartisEntresto$315$60,37453 claims
MerckJanuvia, Janumet$218$45,80145 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$265$44,73664 claims
AbbVieLinzess, Synthroid$847$30,06462 claims
Johnson & JohnsonXarelto$16$27,11035 claims
Lilly USA, LLCMounjaro$693$26,82019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Brooklet

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →